Abbisko Therapeutics Co, Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS11
PHASE 3 / 2-31
RECRUITING6
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO40%
Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Abbisko Therapeutics Co, Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Pimicotinib(ABSK021) NCT05804045 |
P3 | Active, not recruiting | Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis | 94 | 2024-09-23 (-19 mo) |
| Pimicotinib (ABSK021) NCT06111274 |
P2 | Recruiting | Advanced Pancreatic Cancer | 82 | 2025-12-30 |
| ABSK021 NCT06186804 |
P2 | Enrolling by invitation | cGvHD | 64 | 2026-10-30 |
| ABSK-011+BSC NCT07327034 |
P2 | Recruiting | Hepatocellular Carcinoma (HCC) | 141 | 2027-06-30 |
| ABSK043 in combination with Firmonertinib NCT06668103 |
P2 | Recruiting | Non-Small Cell Lung Cancer With EGFR Mutation | 54 | 2027-12-30 (+6 mo) |
| ABSK061 NCT07297875 |
P1/2 | Not yet recruiting | Achondroplasia | 110 | 2028-12-15 |
| ABSK043 in combination with Glecirasib NCT07164170 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 86 | 2028-12-30 |
| ABSK141-400mg NCT07417189 |
P1/2 | Recruiting | Solid Tumors, Adult | 401 | 2028-12-30 |
| ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w NCT05441475 |
P2 | Enrolling by invitation | Hepatocellular Carcinoma | 118 | 2028-12-31 (+53 mo) |
| ABSK061 + ABSK043 NCT06632262 |
P2 | Recruiting | HER2-Gastric/Gastroesophageal Junction Cancer; Urothelial Carcinoma | 202 | 2029-11-30 |
| ABSK043 in combination with Osimertinib NCT07710612 |
P2 | Not yet recruiting | Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive | 72 | 2029-12-31 |